Pembrolizuma (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/11/2018|
|Rapid review completed||07/12/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.|